July 18, 2014
Researchers from the ‘Nutrition Biochemistry: Theurapetic Applications’ group (CTS-461) and the José Mataix Institute for Nutrition and Food Technology at the University of Granada have demonstrated that the administration of three probiotic strains diminishes the accumulation of fat in the liver of obese rats: Lactobacillus paracasei CNCM I-4034, Bifidobacterium breve CNCM I-4035 and Lactobacillus rhamnosus CNCM I-4036.
The accumulation of fat in the liver is called steatosis and it constitutes the first stage in the NAFLD disease, which is closely related to obesity and diabetes. Given that the prevalence of these two pathologies, NAFLD has also become a health problem that affects millions of people throughout the world.
Probiotics are microorganisms (bacteria or yeasts) with healthy effects upon individuals that consume them in adequate doses. They were traditionally considered to be living microorganisms, but the concept was widened since some dead microorganisms, or even their components, can display probiotic properties.
In this current study, the strains were administered during thirty days in the diet of Zucker rats. These rats develop obesity due to a mutation in the gene that codifies the receptor or leptin, a hormone that transmits a sensation of satiety to the organism. Zucker rats are among the best characterized genetic models.
In their article, the authors describe that the administration of probiotics led to lower accumulation of lipids in the liver. “This new finding went hand in hand with lower values in proinflamatory molecules (tumor-a necrosis factor, interleukin 6 and liposacarid) in the serum of rats fed with probiotics.
According to these researchers, this liver disease will not be cured with probiotics, but these microorganisms can certainly be used as support therapy in joint use with other treatments.
This study has been financed by the private company HERO SPAIN S.A.